Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TEVA
BUYTeva Pharmaceutical Industries Limited · Healthcare · Israel · $35.9B · Avg Vol: $194M/d
69
StockRankGet insider-trade alerts
Q
53
V
39
M
71
P/E (TTM)
60.2x
ROE
9.7%
D/E
2.2x
Dividend %
—
COMPANY DESCRIPTION
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.9B | 15.8B | 16.5B | 17.3B | 5.0% | 17.3B | 16.6B | 17.3B | 0.1% |
| EPS | -2.12 | -0.50 | -1.45 | 1.23 | — | 0.60 | 0.90 | 1.29 | 2.4% |
| Shares | 1.1B | 1.1B | 1.1B | 1.1B | +3.5% | 1.2B | — | — | — |
| Debt | 21.6B | 20.2B | 18.1B | 17.1B | -7.4% | 16.9B | — | — | — |
| Equity | 7.8B | 7.5B | 5.4B | 7.9B | 0.5% | — | — | — | — |
| Op CF | 1.6B | 1.4B | 1.2B | 1.6B | 1.2% | 1.9B | — | — | — |
| Inv CF | 656.0M | 968.0M | 792.0M | 737.0M | — | — | — | — | — |
| Fin CF | -1.5B | -1.9B | -1.8B | -2.2B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+8.5%
SMA 50SMA 200
Close
$36.14
RSI (14)
74.2
52W High
$37.35
From 52W High
1.0%
SCORE BREAKDOWN
Quality
53
ROIC
5.9%60.8
ROE
9.7%71.7
GP/Assets
22.3%51.7
Op. Margin
4.0%53.7
FCF/Assets
3.3%61.7
Piotroski
894.0
Int. Cover
1.8x42.5
D/E Ratio
2.18x5.1
Current Ratio
0.88x8.2
Value
39
P/E (TTM)
60.2x17.9
EV/EBITDA
13.0x56.7
P/FCF
26.6x42.7
P/B
5.4x25.9
P/S
2.4x63.8
Div Yield
—N/A
Momentum
71
52W High %
97%93.3
RS 6M
-8%56.3
SMA 50/200
1.07x77.2
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+412%95.1
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$35.9B
P/E (Forward)
11.8x
Gross Margin
52.5%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TEVA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TEVA | Teva Pharmaceutical Industries Limited(you) | $35.9B | 69 | BUY |
| KMDA | Kamada Ltd. | $407M | 83 | STRONG BUY |
| INCR | InterCure Ltd. | $55M | 36 | HOLD |
| BWAY | BrainsWay Ltd. | $641M | 51 | HOLD |
| INMD | InMode Ltd. | $872M | 94 | STRONG BUY |
| DRTS | Alpha Tau Medical Ltd. | $1.1B | 26 | SELL |
| 1696.HK | Sisram Medical Ltd | $134M | 88 | STRONG BUY |
| CGEN | Compugen Ltd. | $216M | 98 | STRONG BUY |
| SLGL | Sol-Gel Technologies Ltd. | $268M | 33 | SELL |
| BVC.L | BATM Advanced Communications Ltd. | $67M | 51 | HOLD |
Peer medians: ROE -6.1% · P/E 9.7x · Gross margin 19.6%